COVID-19 in the heart and the lungs: could we "Notch" the inflammatory storm?

被引：137

作者：

Rizzo, Paola ^{[1
,2
,3
]}

Dalla Sega, Francesco Vieceli ^{[3
]}

Fortini, Francesca ^{[3
]}

Marracino, Luisa ^{[1
,2
]}

Rapezzi, Claudio ^{[3
,4
]}

Ferrari, Roberto ^{[3
,4
]}

机构：

[1] Univ Ferrara, Dept Morphol Surg & Expt Med, Ferrara, Italy

[2] Univ Ferrara, LTTA, Ferrara, Italy

[3] Maria Cecilia Hosp, GVM Care & Res, Cotignola, Italy

[4] Univ Hosp Cona, Cardiovasc Ctr, Ferrara, Italy

来源：

BASIC RESEARCH IN CARDIOLOGY | 2020年 / 115卷 / 03期

关键词：

Coronavirus disease; COVID-19; Cardiovascular disease; Angiotensin-converting enzyme 2; Furin; ADAM17; Notch; CORONAVIRUS; RECEPTOR; ACTIVATION; EXPRESSION; MECHANISM; PATHWAY; ADAM17; TARGET; CANCER; VIRUS;

D O I：

10.1007/s00395-020-0791-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

From January 2020, coronavirus disease (COVID-19) originated in China has spread around the world. The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The presence of myocarditis, cardiac arrest, and acute heart failure in COVID-19 patients suggests the existence of a relationship between SARS-CoV-2 infection and cardiac disease. The Notch signalling is a major regulator of cardiovascular function and it is also implicated in several biological processes mediating viral infections. In this report we discuss the possibility to target Notch signalling to prevent SARS-CoV-2 infection and interfere with the progression of COVID-19- associated heart and lungs disease.

引用

页数：8

共 55 条

[1] Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme [J].